As of Friday, December 26, Alterity Therapeutics Limited’s ATHE share price has dipped by 6.30%, which has investors questioning if this is right time to buy.

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a ...

Welcome to the second installment of this comprehensive annual look at global cybersecurity industry prediction reports from ...

If Opposition wants a credible image, it should eschew intellectual dishonestyWithreference to ‘Bold Talk’ ( THI, Dec 27), it ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Your brain doesn't have to age on autopilot. New research shows we can slow—and potentially reverse—brain aging.

As the immune system weakens with age, scientists have found a way to restore some of its lost strength. By delivering mRNA ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of ...

Forbes contributors publish independent expert analyses and insights. Kris Holt is a writer who covers video games and word games. It’s the time of year when the likes of Spotify Wrapped and Apple ...

Apple is now recommending that users update from iOS 18 to the newer iOS 26 operating system. The iOS 26 update includes a new "Liquid Glass" interface, call screening features, and upgrades to Apple ...